Literature DB >> 2912562

In vitro hepatotoxicity of SR 4233 (3-amino-1,2,4-benzotriazine-1,4-dioxide), a hypoxic cytotoxin and potential antitumor agent.

A K Costa1, M A Baker, J M Brown, J R Trudell.   

Abstract

SR 4233 (3-amino-1,2,4-benzotriazine-1,4-dioxide) is presently undergoing investigation as an antitumor agent because of its high selective toxicity for hypoxic cells in vitro and in vivo. It has been found to be 15 to 200 times more toxic to hypoxic rodent and human cell lines than their normoxic counterparts. We investigated the toxicity of SR 4233 in primary cultures of hepatocytes under various oxygen tensions, ranging from 1% to 20% oxygen. The 50% lethal dose of SR 4233 was found to be 50 times lower in hepatocyte monolayers at 1% O2 versus 20% O2. Even at 4% O2, a concentration that prevails in the pericentral area of the liver under conditions of normal blood flow, SR 4233 was an order of magnitude more toxic than at 20% O2. All samples were analyzed for metabolites, and metabolism was found to be dependent on both the SR 4233 concentration and the oxygen tension. Formation of the major metabolite SR 4317 occurred to the greatest extent at the lowest oxygen concentration and the highest SR 4233 concentration. Very little metabolism occurred at 10 to 20% O2, which is in agreement with data in Chinese hamster ovary cells under aerobic conditions.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2912562

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  DNA strand cleaving properties and hypoxia-selective cytotoxicity of 7-chloro-2-thienylcarbonyl-3-trifluoromethylquinoxaline 1,4-dioxide.

Authors:  Venkatraman Junnotula; Anuruddha Rajapakse; Leire Arbillaga; Adela López de Cerain; Beatriz Solano; Raquel Villar; Antonio Monge; Kent S Gates
Journal:  Bioorg Med Chem       Date:  2010-03-19       Impact factor: 3.641

2.  Acute lesions in rats caused by 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233) or nitromin: a comparison with rates of reduction in microsomal systems from target organs.

Authors:  I N White; A Cahill; A Davies; P Carthew
Journal:  Arch Toxicol       Date:  1992       Impact factor: 5.153

Review 3.  Hypoxia and drug resistance.

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1994-06       Impact factor: 9.264

4.  The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumours.

Authors:  E Lartigau; M Guichard
Journal:  Br J Cancer       Date:  1996-06       Impact factor: 7.640

5.  Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?

Authors:  E C Chinje; A V Patterson; M P Saunders; S D Lockyer; A L Harris; I J Stratford
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

6.  Metabolism of the bioreductive cytotoxin SR 4233 by tumour cells: enzymatic studies.

Authors:  J Wang; K A Biedermann; C R Wolf; J M Brown
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

7.  Molecular mechanisms of SR 4233-induced hepatocyte toxicity under aerobic versus hypoxic conditions.

Authors:  J M Silva; P J O'Brien
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

Review 8.  SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.

Authors:  J M Brown
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

9.  Molecular mechanisms of tirapazamine (SR 4233, Win 59075)-induced hepatocyte toxicity under low oxygen concentrations.

Authors:  S Khan; P J O'Brien
Journal:  Br J Cancer       Date:  1995-04       Impact factor: 7.640

10.  Phase I Trial on Arterial Embolization with Hypoxia Activated Tirapazamine for Unresectable Hepatocellular Carcinoma.

Authors:  Nadine Abi-Jaoudeh; Farshid Dayyani; Pei Jer Chen; Dayantha Fernando; Nicholas Fidelman; Hanna Javan; Po-Chin Liang; Jen-I Hwang; David K Imagawa
Journal:  J Hepatocell Carcinoma       Date:  2021-05-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.